A dipeptide YY derived from royal jelly proteins inhibits renin activity

International Journal of Molecular Medicine

Volumn 21, Issue 6, 2008, Pages 677-681

  Sultana, Afroza ^a   Nabi, A H M Nurun ^a   Nasir, Uddin M ^a   Maruyama, Hiroe ^b   Suzuki, Kazu Michi ^b   Mishima, Satoshi ^b   Suzuki, Fumiaki ^a  

^a GIFU UNIVERSITY   (Japan)

^b Api Company Ltd   (Japan)

Author keywords

Dipeptide YY; Renin inhibitor; Royal jelly peptide

Indexed keywords

ANGIOTENSINOGEN; PEPTIDE YY; PROTEINASE; RENIN; ROYAL JELLY; COMPLEMENTARY DNA; DIPEPTIDE; FATTY ACID; INSECT PROTEIN; PEPTIDE HYDROLASE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; BLOOD PRESSURE; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; CRICETULUS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TRANSFER; GENE VECTOR; GENETICS; HAMSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHEEP;

ANGIOTENSINOGEN; ANIMALS; BLOOD PRESSURE; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CRICETULUS; DIPEPTIDES; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; HYPERTENSION; INSECT PROTEINS; MOLECULAR STRUCTURE; PEPTIDE HYDROLASES; RATS; RATS, INBRED SHR; RECOMBINANT PROTEINS; RENIN; RENIN-ANGIOTENSIN SYSTEM; SHEEP;

EID: 47649087241     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.21.6.677     Document Type: Article

References (35)

1. Skeggs LT, Dorer FE, Levine M, Lentz KE and Kahn JR: The biochemistry of the renin-angiotensin system. Adv Exp Med Biol 130: 1-27, 1980.
2. Bader M and Ganten D: Regulation of renin: new evidence from cultured cells and genetically modified mice. J Mol Med 78: 130-139, 2000.
3. Corvol P and Jeunemaitre X: Molecular genetics of human hypertension: role of angiotensinogen. Endocr Rev 18: 662-677, 1997.
4. Kim S and Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34, 2000.
5. Ichiki T: Role of renin angiotensin system in angiogenesis: it is still elusive. Arterioscler Thromb Vasc Biol 24: 622-624, 2004.
6. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V and Egido J: Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900, 2003.
7. Kamakura M, Fukuda T, Fukushima M and Yonekura M: Storage-dependent degradation of 57-kDa protein in royal jelly: a possible marker for freshness. Biosci Biotechnol Biochem 65: 277-284, 2001.
8. Fujii A, Kobayashi S, Kuboyama N, et al: Augmentation of wound healing by royal jelly (RJ) in streptozotocin-diabetic rats. Jpn J Pharmacol 53: 331-337, 1990.
9. Maruyama H, Tokunaga K, Suzuki K, Yoshida C, Futamura Y, Araki Y and Mishima S: Purification and identification of angiotensin I-converting enzyme inhibitory peptides from royal jelly treated with protease. Nippon Shokuhin Kagaku Kogaku Kaishi (in Japanese) 50: 310-315, 2003.
10. Suzuki K, Yoshida C, Tokunaga K, Maruyama H, Futamura Y, Araki Y and Mishima S: Inhibition of angiotensin I-converting enzyme by protease digests from royal jelly. Nippon Shokuhin Kagaku Kogaku Kaishi (in Japanese), 50: 286-288, 2003.
11. Tokunaga K, Suzuki K, Yoshida C, Maruyama H, Futamura Y, Araki Y and Mishima S: Antihypertensive mechanism of royal jelly treated with protease in spontaneously hypertensive rats. Nippon Shokuhin Kagaku Kogaku Kaishi (in Japanese) 51: 34-37, 2004.
12. Tokunaga K, Yoshida C, Suzuki K, Maruyama H, Futamura Y, Araki Y and Mishima S: Antihypertensive effect of peptide from royal jelly in spontaneously hypertensive rats. Biol Pharm Bull 27: 189-192, 2004.
13. Keim GR Jr, Kirpan J, Peterson AE, Murphy BF, Hassert GL Jr and Poutsiaka JW: Inhibition of angiotensin I-initiated hemodynamic changes in anesthetized dogs by a synthetic nonapeptide. Proc Soc Exp Biol Med 140: 149-152, 1972.
14. Ondetti MA, Rubin B and Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441-444, 1977.
15. Rubin B, Laffan RJ, Kotler DG, O'Keefe EH, Demaio DA and Goldberg ME: SQ 14,225 (D-3-mercapto-2-methylpropanoyl-1-proline), a novel orally active inhibitor of angiotensin I-converting enzyme. J Pharmacol Exp Ther 204: 271-280, 1978.
16. Swartz SL, Williams GH, Hollenberg NK, Moore TJ and Dluhy RG: Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation. Hypertension 1: 106-111, 1979.
17. Cushman DW, Chueng HS, Sabo EF and Ondetti MA: Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16: 5484-5491, 1977.
18. Cumin F, Evin G, Fehrentz JA, Seyer R, Castro B, Menard J and Corvol P: Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem 260: 9154-9157, 1995.
19. Burton J, Poulsen K and Haber E: Competitive inhibitors of renin. Inhibitors effective at physiological pH. Biochemistry 14: 3892-3898, 1975.
20. Haber E and Burton J: Inhibitors of renin and their utility in physiologic studies: Fed Proc 38: 2768-2773, 1979.
21. Kleinert HD: Renin inhibition. Cardiovasc Drugs Ther 9: 645-655, 1995.
22. Hershey JC, Steiner B, Fischli W and Feuerstein G: Renin inhibitors: an antihypertensive strategy on the verge of reality. Drug Discov Today 2: 181-185, 2005.
23. Nagase M, Suzuki F, Sawai Y, Orihashi T, Inui Y, Nakagawa T and Nakamura Y: Purification and some properties of recombinant sheep angiotensinogen expressed in Chinese hamster ovary cells. Biomed Res 18: 439-443, 2000.
24. Nasir UM, Takahashi K, Nagai T, Nakagawa T, Suzuki F and Nakamura Y: Two peaks in pH dependence of renin-angiotensinogen reaction. Biosci Biotechnol Biochem 62: 338-340, 1998.
25. Inui Y, Orihashi T, Nakagawa T, Ebibara A, Suzuki F and Nakamura Y: Effect of glycosylation of the residue at position 14 in ovine angiotensinogen on human renin reaction. Biosci Biotechnol Biochem 62: 1612-1614, 1998.
26. Ebihara A, Nasir UM, Yoshida S, et al: Sialic acid residue of ovine angiotensinogen does not affect the reactivity to human renin. Biomed Res 21: 105-109, 2000.
27. Suzuki F, Yamashita S, Takahashi A, Ito M, Miyazaki S, Nagata Y and Nakamura Y: Highly sensitive microplate-ELISA for angiotensin I using 3,3′, 5,5′-tetramethylbenzidine. Clin Exp Hypertens A 12: 83-95, 1990.
28. Mishima S, Yoshida C, Akino S and Sakamoto T: Anti-hypertensive effects of Brazilian propolis: identification of caffeoylquinic acids as constituents involved in the hypotension in spontaneously hypertensive rats. Biol Pharm Bull 28: 1909-1914, 2005.
29. Staessen JA, Li Y, Thijs L and Wang JG: Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 28: 385-407, 2005.
30. Jeunemaitre X, Ménard J, Nussberger J, Guyene TT, Brunner HR and Corvol P: Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens 2: 819-827, 1989.
31. Matsui T, Yukiyoshi A, Doi S, Sugimoto H, Yamada H and Matsumoto K: Gastrointestinal enzyme production of bioactive peptides from royal jelly protein and their antihypertensive ability in SHR. J Nutr Biochem 13: 80-86, 2002.
32. Gross F, Lazar J and Orth H: Inhibition of the renin-angiotensinogen reaction by pepstatin. Science 175: 656, 1972.
33. Staessen JA, Li Y and Richart T: Oral renin inhibitors. Lancet 368: 1449-1456, 2006. Erratum in: Lancet 368: 2124, 2006.
34. Nasir UM, Suzuki F, Nagai T, Nakagawa T and Nakamura Y: Tyrosin-83 of human renin contributes to biphasic pH dependence of the renin-angiotensinogen reaction. Biosci Biotechnol Biochem 63: 1143-1145, 1999.
35. Dhanaraj V, Dealwis CG, Frazao C, et al: X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature 357: 466-472, 1992.